REFERENCES
1. Kosanović M, Milutinovic B, Glamočlija S, Morlans IM, Ortiz A, Bozic M. Extracellular vesicles and acute kidney injury: potential therapeutic avenue for renal repair and regeneration. IJMS. 2022;23:3792.
2. Reiss AB, Jacob B, Zubair A, Srivastava A, Johnson M, De Leon J. Fibrosis in chronic kidney disease: pathophysiology and therapeutic targets. JCM. 2024;13:1881.
3. Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392:2052-90.
4. Qi R, Yang C. Renal tubular epithelial cells: the neglected mediator of tubulointerstitial fibrosis after injury. Cell Death Dis. 2018;9:1126.
5. Li ZL, Li XY, Zhou Y, Wang B, Lv LL, Liu BC. Renal tubular epithelial cells response to injury in acute kidney injury. EBioMedicine. 2024;107:105294.
6. Zou Y, Yiu WH, Lok SWY, et al. Tubular FoxP2 and kidney fibrosis. J Am Soc Nephrol. 2025;36:544-58.
7. Lake BB, Menon R, Winfree S, et al; KPMP Consortium. An atlas of healthy and injured cell states and niches in the human kidney. Nature. 2023;619:585-94.
8. Clark JZ, Chen L, Chou CL, Jung HJ, Lee JW, Knepper MA. Representation and relative abundance of cell-type selective markers in whole-kidney RNA-Seq data. Kidney Int. 2019;95:787-96.
9. Balzer MS, Rohacs T, Susztak K. How many cell types are in the kidney and what do they do? Annu Rev Physiol. 2022;84:507-31.
10. Koh ES, Chung S. Recent update on acute kidney injury-to-chronic kidney disease transition. Yonsei Med J. 2024;65:247-56.
11. Liu BC, Tang TT, Lv LL, Lan HY. Renal tubule injury: a driving force toward chronic kidney disease. Kidney Int. 2018;93:568-79.
12. Zhou J, Shi Y. Mesenchymal stem/stromal cells (MSCs): origin, immune regulation, and clinical applications. Cell Mol Immunol. 2023;20:555-7.
13. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant. 1995;16:557-64.
14. Ceccotti E, Quaglia M, Camussi G, Bruno S. Mesenchymal stem cells derived extracellular vesicles for chronic kidney disease: pleiotropic mechanisms of actions of a versatile therapy. Front Bioeng Biotechnol. 2025;13:1612193.
15. Zheng Y, Wang H, Li X, Xie J, Fan J, Ren S. Extracellular vesicles in chronic kidney disease: diagnostic and therapeutic roles. Front Pharmacol. 2024;15:1371874.
16. Kosanović M, Milutinović B, Kutzner TJ, Mouloud Y, Bozic M. Clinical prospect of mesenchymal stromal/stem cell-derived extracellular vesicles in kidney disease: challenges and the way forward. Pharmaceutics. 2023;15:1911.
17. Welsh JA, Goberdhan DCI, O'Driscoll L, et al; MISEV Consortium. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024;13:e12404.
18. Barr SI, Abd El-Azeem EM, Bessa SS, Mohamed TM. Role of exosomes in pathogenesis, diagnosis, and treatment of diabetic nephropathy. BMC Nephrol. 2025;26:230.
19. Battistelli M, Falcieri E. Apoptotic bodies: particular extracellular vesicles involved in intercellular communication. Biology. 2020;9:21.
20. Witwer KW, Van Balkom BWM, Bruno S, et al. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. J Extracell Vesicles. 2019;8:1609206.
21. Tang T, Zhang Y, Crowley SD, Lv L, Liu B. Shedding light on the role of extracellular vesicles in renal fibrosis. Fundam Res. 2024;Epub ahead of print.
22. Huang Y, Yang L. Mesenchymal stem cells and extracellular vesicles in therapy against kidney diseases. Stem Cell Res Ther. 2021;12:219.
23. Birtwistle L, Chen XM, Pollock C. Mesenchymal stem cell-derived extracellular vesicles to the rescue of renal injury. Int J Mol Sci. 2021;22:6596.
24. Convento MB, de Oliveira AS, Boim MA, Borges FT. Umbilical cord mesenchymal stem cell-derived extracellular vesicles as natural nanocarriers in the treatment of nephrotoxic injury in vitro. Cells. 2024;13:1658.
25. Cao JY, Wang B, Tang TT, et al. Exosomal miR-125b-5p deriving from mesenchymal stem cells promotes tubular repair by suppression of p53 in ischemic acute kidney injury. Theranostics. 2021;11:5248-66.
26. Hong S, Kim H, Kim J, Kim S, Park TS, Kim TM. Extracellular vesicles from induced pluripotent stem cell-derived mesenchymal stem cells enhance the recovery of acute kidney injury. Cytotherapy. 2024;26:51-62.
27. Yin S, Zhou S, Ren D, et al. Mesenchymal stem cell-derived exosomes attenuate epithelial-mesenchymal transition of HK-2 cells. Tissue Eng Part A. 2022;28:651-9.
28. Bian Z, Wang X, Zhu R, Chen S. miR-21-5p in extracellular vesicles obtained from adipose tissue-derived stromal cells facilitates tubular epithelial cell repair in acute kidney injury. Cytotherapy. 2023;25:310-22.
29. Liang M, Zhang D, Zheng D, He W, Jin J. Exosomes from miR-374a-5p-modified mesenchymal stem cells inhibit the progression of renal fibrosis by regulating MAPK6/MK5/YAP axis. Bioengineered. 2022;13:4517-27.
30. Wang W, Wang J, Liao D. Effects and mechanisms of extracellular vesicles in different models of acute kidney injury. Stem Cells Int. 2025;2025:1075016.
31. Lindoso RS, Collino F, Bruno S, et al. Extracellular vesicles released from mesenchymal stromal cells modulate miRNA in renal tubular cells and inhibit ATP depletion injury. Stem Cells Dev. 2014;23:1809-19.
32. Tomasoni S, Longaretti L, Rota C, et al. Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells. Stem Cells Dev. 2013;22:772-80.
33. Mao J, Li C, Wu F, et al. MSC-EVs transferring mitochondria and related components: a new hope for the treatment of kidney disease. Front Immunol. 2022;13:978571.
34. Yu Y, Chen M, Guo Q, et al. Human umbilical cord mesenchymal stem cell exosome-derived miR-874-3p targeting RIPK1/PGAM5 attenuates kidney tubular epithelial cell damage. Cell Mol Biol Lett. 2023;28:12.
35. Tang TT, Wang B, Li ZL, et al. Kim-1 targeted extracellular vesicles: a new therapeutic platform for RNAi to Treat AKI. J Am Soc Nephrol. 2021;32:2467-83.
36. Huang TY, Chien MS, Su WT. Therapeutic potential of pretreatment with exosomes derived from stem cells from the apical papilla against cisplatin-induced acute kidney injury. Int J Mol Sci. 2022;23:5721.
37. Li JK, Yang C, Su Y, et al. Mesenchymal stem cell-derived extracellular vesicles: a potential therapeutic strategy for acute kidney injury. Front Immunol. 2021;12:684496.
38. Nho JH, Jung HK, Lee MJ, et al. Beneficial effects of cynaroside on cisplatin-induced kidney injury in vitro and in vivo. Toxicol Res. 2018;34:133-41.
39. Wang SY, Xu Y, Hong Q, Chen XM, Cai GY. Mesenchymal stem cells ameliorate cisplatin-induced acute kidney injury via let-7b-5p. Cell Tissue Res. 2023;392:517-33.
40. Liang J, Liu Y. Animal models of kidney disease: challenges and perspectives. Kidney360. 2023;4:1479-93.
41. Wang B, Jia H, Zhang B, et al. Pre-incubation with hucMSC-exosomes prevents cisplatin-induced nephrotoxicity by activating autophagy. Stem Cell Res Ther. 2017;8:75.
42. Zhao M, Liu S, Wang C, et al. Mesenchymal stem cell-derived extracellular vesicles attenuate mitochondrial damage and inflammation by stabilizing mitochondrial DNA. ACS Nano. 2021;15:1519-38.
43. Lopes JA, Collino F, Rodrigues-Ferreira C, et al. Early effects of extracellular vesicles secreted by adipose tissue mesenchymal cells in renal ischemia followed by reperfusion: mechanisms rely on a decrease in mitochondrial anion superoxide production. Int J Mol Sci. 2022;23:2906.
44. Mu YF, Mao ZH, Pan SK, et al. Macrophage-driven inflammation in acute kidney injury: therapeutic opportunities and challenges. Transl Res. 2025;278:1-9.
45. Eirin A, Zhu XY, Puranik AS, et al. Mesenchymal stem cell-derived extracellular vesicles attenuate kidney inflammation. Kidney Int. 2017;92:114-24.
46. Guo Q, Li P, Chen M, et al. Exosomes from human umbilical cord stem cells suppress macrophage-to-myofibroblast transition, alleviating renal fibrosis. Inflammation. 2024;47:2094-107.
47. Jeon JS, Kim E, Bae YU, et al. microRNA in extracellular vesicles released by damaged podocytes promote apoptosis of renal tubular epithelial cells. Cells. 2020;9:1409.
48. Kang M, Jordan V, Blenkiron C, Chamley LW. Biodistribution of extracellular vesicles following administration into animals: a systematic review. J Extracell Vesicles. 2021;10:e12085.
49. Liu Y, Cui J, Wang H, et al. Enhanced therapeutic effects of MSC-derived extracellular vesicles with an injectable collagen matrix for experimental acute kidney injury treatment. Stem Cell Res Ther. 2020;11:161.
50. Malvicini R, De Lazzari G, Tolomeo AM, et al. Influence of the isolation method on characteristics and functional activity of mesenchymal stromal cell-derived extracellular vesicles. Cytotherapy. 2024;26:157-70.
51. Llorens-Revull M, Martínez-González B, Quer J, et al. Comparison of extracellular vesicle isolation methods for miRNA sequencing. Int J Mol Sci. 2023;24:12183.
52. Clos-Sansalvador M, Monguió-Tortajada M, Roura S, Franquesa M, Borràs FE. Commonly used methods for extracellular vesicles’ enrichment: implications in downstream analyses and use. Eur J Cell Biol. 2022;101:151227.
53. Wang SJ, Qiu ZZ, Chen FW, et al. Bone marrow mesenchymal stem cell-derived extracellular vesicles containing miR-181d protect rats against renal fibrosis by inhibiting KLF6 and the NF-κB signaling pathway. Cell Death Dis. 2022;13:535.
54. Gupta D, Zickler AM, El Andaloussi S. Dosing extracellular vesicles. Adv Drug Deliv Rev. 2021;178:113961.
55. Noda P, Francini ALR, Teles F, et al. Extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) as adjuvants in the treatment of chronic kidney disease (CKD). Cells. 2025;14:434.
56. Zou X, Gu D, Xing X, Cheng Z, Gong D, Zhang G. Human mesenchymal stromal cell-derived extracellular vesicles alleviate renal ischemic reperfusion injury and enhance angiogenesis in rats. Am J Transl Res. 2016;8:4289-99.
57. Hu X, Shen N, Liu A, et al. Bone marrow mesenchymal stem cell-derived exosomal miR-34c-5p ameliorates RIF by inhibiting the core fucosylation of multiple proteins. Mol Ther. 2022;30:763-81.
58. Shi L, Hu Y, Zeng H, et al. Mesenchymal stem cell-derived extracellular vesicles ameliorate renal interstitial fibrosis via the miR-13474/ADAM17 axis. Sci Rep. 2024;14:17703.
59. Zhang X, Zhao J, Ge R, et al. Arg-Gly-Asp engineered mesenchymal stem cells as targeted nanotherapeutics against kidney fibrosis by modulating m6A. Acta Biomater. 2025;198:85-101.
60. Gao Z, Zhang C, Peng F, et al. Hypoxic mesenchymal stem cell-derived extracellular vesicles ameliorate renal fibrosis after ischemia-reperfusion injure by restoring CPT1A mediated fatty acid oxidation. Stem Cell Res Ther. 2022;13:191.
61. Cao H, Cheng Y, Gao H, et al.
62. Cui C, Zang N, Song J, et al. Exosomes derived from mesenchymal stem cells attenuate diabetic kidney disease by inhibiting cell apoptosis and epithelial-to-mesenchymal transition via miR-424-5p. FASEB J. 2022;36:e22517.
63. Kim H, Hong S, Kim S, Kim TM. Extracellular vesicles from induced mesenchymal stem cells inhibit acute kidney injury to chronic kidney disease transition. Int J Stem Cells. 2025;18:286-300.
64. Kim SH, Kim CH, Lee CH, et al. Glycoengineered stem cell-derived extracellular vesicles for targeted therapy of acute kidney injury. Biomaterials. 2025;318:123165.
65. Deng XH, Wu ZC, Sun Q, et al. The effects of Klotho delivering mesenchymal stem cell-derived small extracellular vesicles on acute kidney injury. J Nanobiotechnology. 2025;23:427.
66. Yang Y, Wang J, Zhang Y, Hu X, Li L, Chen P. Exosomes derived from mesenchymal stem cells ameliorate renal fibrosis via delivery of miR-186-5p. Hum Cell. 2022;35:83-97.
67. Matsushita K, Toyoda T, Akane H, Morikawa T, Ogawa K. Role of CD44 expressed in renal tubules during maladaptive repair in renal fibrogenesis in an allopurinol-induced rat model of chronic kidney disease. J Appl Toxicol. 2024;44:455-69.
68. Huang Y, Wang J, Jiang K, Chung EJ. Improving kidney targeting: the influence of nanoparticle physicochemical properties on kidney interactions. J Control Release. 2021;334:127-37.
69. Huang Y, Ning X, Ahrari S, et al. Physiological principles underlying the kidney targeting of renal nanomedicines. Nat Rev Nephrol. 2024;20:354-70.
